ACVR1B

Across TCGA pan-cancer cohorts, ACVR1B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ACVR1B data layer compared with 16 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACVR1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACVR1B expression acts as an unfavorable survival marker.

LUAD, KIRC, and HNSC are the cancer types where ACVR1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.217	0.688	<.001	64	view →
KIRC	OS	Median	All	0.144	0.806	<.001	42	view →
HNSC	OS	Median	II,III,IV	0.244	0.651	.006	24	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
COAD	OS	Median	IV	0.056	0.649	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
SKCM	OS	Median	III,IV	0.175	0.705	.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ACVR1B–LUAD (OS)

Open the LUAD breakdown →